Co-Zincretin 50/500/Co-Zincretin 50/1000/Co-Zincretin XR 100/1000 Contraindications

Co-Zincretin 50/500/Co-Zincretin XR 100/1000: Sitagliptin Phosphate + Metformin HCl is contraindicated in patients with: Severe renal impairment, (eGFR <30 mL/min/1.73 m²) (see Metformin hydrochloride: Renal Impairment under Precautions).
Known hypersensitivity to sitagliptin phosphate, metformin hydrochloride known hypersensitivity to sitagliptin phosphate, metformin hydrochloride or any other component of Sitagliptin Phosphate + Metformin HCl (see Sitagliptin phosphate: Hypersensitivity Reactions under Precautions and Post-Marketing Experience under Adverse Reactions).
Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Sitagliptin Phosphate + Metformin HCl should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because the use of such products may result in acute alteration of renal function (see Metformin hydrochloride under Precautions).
Co-Zincretin 50/1000: Contraindicated in patients with: Hypersensitivity to the active substances or to any of the excipients; diabetic ketoacidosis, diabetic pre-coma; moderate and severe renal impairment (creatinine clearance <6 mL/min); acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock, intravascular administration of iodinated contrast agents; acute or chronic disease which may cause tissue hypoxia such as: cardiac or respiratory failure, recent myocardial infarction, hepatic impairment; acute alcohol intoxication, alcoholism; breast-feeding.